CN117599134A - 一种抗氧化辅助降血糖的中药组合物及其制备方法和应用 - Google Patents
一种抗氧化辅助降血糖的中药组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN117599134A CN117599134A CN202311498090.7A CN202311498090A CN117599134A CN 117599134 A CN117599134 A CN 117599134A CN 202311498090 A CN202311498090 A CN 202311498090A CN 117599134 A CN117599134 A CN 117599134A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- weight
- following components
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 50
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 239000008280 blood Substances 0.000 title claims abstract description 37
- 210000004369 blood Anatomy 0.000 title claims abstract description 37
- 230000001603 reducing effect Effects 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 238000007254 oxidation reaction Methods 0.000 title abstract description 10
- 239000000284 extract Substances 0.000 claims abstract description 158
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 17
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims abstract description 16
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 15
- 235000005412 red sage Nutrition 0.000 claims abstract description 15
- 235000009467 Carica papaya Nutrition 0.000 claims abstract description 14
- 240000001008 Dimocarpus longan Species 0.000 claims abstract description 14
- 235000000235 Euphoria longan Nutrition 0.000 claims abstract description 14
- 244000183278 Nephelium litchi Species 0.000 claims abstract description 14
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 14
- 241001061264 Astragalus Species 0.000 claims abstract description 13
- 229920001661 Chitosan Polymers 0.000 claims abstract description 13
- 241000233779 Cyclocarya paliurus Species 0.000 claims abstract description 13
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims abstract description 13
- 244000302512 Momordica charantia Species 0.000 claims abstract description 13
- 235000009811 Momordica charantia Nutrition 0.000 claims abstract description 13
- 235000009812 Momordica cochinchinensis Nutrition 0.000 claims abstract description 13
- 235000018365 Momordica dioica Nutrition 0.000 claims abstract description 13
- 235000015742 Nephelium litchi Nutrition 0.000 claims abstract description 13
- 235000006533 astragalus Nutrition 0.000 claims abstract description 13
- 210000004233 talus Anatomy 0.000 claims abstract description 13
- 241000405414 Rehmannia Species 0.000 claims abstract description 12
- 239000008517 radix Trichosanthis Substances 0.000 claims abstract description 12
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 10
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 10
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 10
- 240000002948 Ophiopogon intermedius Species 0.000 claims abstract description 10
- 240000000103 Potentilla erecta Species 0.000 claims abstract description 10
- 235000016551 Potentilla erecta Nutrition 0.000 claims abstract description 10
- 244000234609 Portulaca oleracea Species 0.000 claims abstract description 9
- 235000001855 Portulaca oleracea Nutrition 0.000 claims abstract description 9
- 244000215554 Nepeta hederacea Species 0.000 claims abstract description 7
- 235000011755 Nepeta hederacea Nutrition 0.000 claims abstract description 7
- 241000756042 Polygonatum Species 0.000 claims abstract description 7
- 235000008737 Polygonatum biflorum Nutrition 0.000 claims abstract description 7
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 claims abstract description 6
- 235000006008 Brassica napus var napus Nutrition 0.000 claims abstract description 6
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 claims abstract description 6
- 235000004977 Brassica sinapistrum Nutrition 0.000 claims abstract description 6
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 4
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 4
- 240000006432 Carica papaya Species 0.000 claims abstract 4
- 240000000385 Brassica napus var. napus Species 0.000 claims abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 77
- 238000002156 mixing Methods 0.000 claims description 44
- 238000005303 weighing Methods 0.000 claims description 31
- 238000001035 drying Methods 0.000 claims description 27
- 230000002829 reductive effect Effects 0.000 claims description 25
- 239000000706 filtrate Substances 0.000 claims description 24
- 238000001914 filtration Methods 0.000 claims description 24
- 238000000605 extraction Methods 0.000 claims description 22
- 239000002994 raw material Substances 0.000 claims description 19
- 206010012601 diabetes mellitus Diseases 0.000 claims description 16
- 238000002791 soaking Methods 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 11
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 8
- 241000222336 Ganoderma Species 0.000 claims description 7
- 244000046146 Pueraria lobata Species 0.000 claims description 7
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 6
- 235000003351 Brassica cretica Nutrition 0.000 claims description 5
- 235000003343 Brassica rupestris Nutrition 0.000 claims description 5
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 claims description 5
- 235000010460 mustard Nutrition 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 244000056139 Brassica cretica Species 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 21
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 15
- 239000008103 glucose Substances 0.000 description 14
- 241000219173 Carica Species 0.000 description 10
- 229940079593 drug Drugs 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 210000004923 pancreatic tissue Anatomy 0.000 description 6
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 5
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 5
- 230000003064 anti-oxidating effect Effects 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 229930003944 flavone Natural products 0.000 description 5
- 150000002212 flavone derivatives Chemical class 0.000 description 5
- 235000011949 flavones Nutrition 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 229940118019 malondialdehyde Drugs 0.000 description 5
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 5
- 241000219198 Brassica Species 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 229920000881 Modified starch Polymers 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 244000275904 brauner Senf Species 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 239000003538 oral antidiabetic agent Substances 0.000 description 2
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 244000178993 Brassica juncea Species 0.000 description 1
- 235000005855 Brassica juncea var. subintegrifolia Nutrition 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241001571466 Potentilla discolor Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000000081 effect on glucose Effects 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000007613 slurry method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/732—Chaenomeles, e.g. flowering quince
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种抗氧化辅助降血糖的中药组合物及制备方法和应用，包括按重量百分比计：提取物A 20‑30％、提取物B 20‑30％、提取物C 15％、提取物D 15％、提取物E 10‑20％；所述提取物A，包括按重量份计：生黄芪10‑30份、生地10‑20份、苍术5‑10份、葛根10‑20份、丹参10‑20份、青钱柳5‑10份、苦瓜10‑30份、壳聚糖5‑15份；所述提取物B，包括按重量份计：连钱草20‑40份、杞子根20‑40份、马齿苋10‑30份、芥菜花10‑30份、玉竹10‑30份、麦冬10‑30份、天花粉10‑30份、丹参10‑30份；所述提取物C，包括按重量份计：龙眼核20‑40份、荔枝核20‑40份、木瓜核20‑40份；所述提取物D，包括按重量份计：翻白草100‑300份；所述提取物E，包括按重量百分比计：灵芝提取物1‑10％、EGCG 5‑20％。本发明将抗氧化物质与中药复方结合，具有显著降血糖和抗氧化效果。
Description
技术领域
本发明涉及中药技术领域，尤其涉及一种抗氧化辅助降血糖的中药组合物及其制备方法和应用。
背景技术
糖尿病是一组以长期高血糖为主要特征的代谢综合征，是由遗传因素和环境因素长期相互作用所引起的胰岛素分泌不足或作用缺陷，以血中葡萄糖水平升高为生化特征及多饮、多食、多尿、消瘦乏力为临床表现的代谢紊乱综合群。糖尿病主要发病机制有胰岛素抵抗、糖脂代谢异常、炎症反应、氧化应激、遗传因素等。
现在临床上采用的糖尿病治疗方法通常只注重降低患者的血糖，很少考虑如何改善靶器官和胰岛的功能。患者长期服用口服降糖药，对于逐渐下降的胰岛功能，有如“鞭打疲惫的马”。且临床常用的口服降糖药多属于化学药品，易导致并发症，且对人体会造成不可逆的伤害。随着医学技术的不断发展，中药治疗糖尿病被越来越多的医学人士所关注，此种治疗方式产生的副作用较小，因此被大多数患者所接受。
近年来，抗氧化在糖尿病治疗中的作用越来越受到重视。糖尿病患者在长期高血糖浸润的环境中，由于代谢紊乱影响了清除自由基的各种抗氧化酶的活性和表达，以至于自由基不能及时被清除，并在组织细胞中蓄积，引起细胞器如线粒体、内质网等损伤，进而细胞的生理功能发生障碍，甚至会启动凋亡程序。其中以活性氧簇为代表的氧自由基在糖尿病中扮演极为重要的角色。因此，通过调控改善糖尿病患者体内的氧化应激状态，抑制或逆转自由基对组织细胞的损伤作用，能在防治糖尿病进展中发挥积极作用。中医学中虽然没有“抗氧化”的说法，但大量临床研究表明，中药的某些成分也具有抗氧化作用，对于糖尿病的治疗具有一定的效果，但目前仍缺乏兼具有效降血糖和保护胰脏的中药组方。
发明内容
本发明所要解决的技术问题是：本发明提供一种抗氧化辅助降血糖的中药组合物及其制备方法和应用，实现降血糖的同时改善氧化应激，保护和加强胰脏功能，疗效显著，且无其他不良反应及毒副作用。
为了解决上述技术问题，本发明采用的技术方案为：
本发明提供一种抗氧化辅助降血糖的中药组合物，包括按重量百分比计的：
提取物A 20-30％、提取物B 20-30％、提取物C15％、提取物D15％、提取物E10-20％；
所述提取物A，包括按重量份计的：生黄芪10-30份、生地10-20份、苍术5-10份、葛根10-20份、丹参10-20份、青钱柳5-10份、苦瓜10-30份、壳聚糖5-15份；
所述提取物B，包括按重量份计的：连钱草20-40份、杞子根20-40份、马齿苋10-30份、芥菜花10-30份、玉竹10-30份、麦冬10-30份、天花粉10-30份、丹参10-30份；
所述提取物C，包括按重量份计的：龙眼核20-40份、荔枝核20-40份、木瓜核20-40份；
所述提取物D，包括按重量份计的：翻白草100-300份；
所述提取物E，包括按重量百分比计的：灵芝提取物1-10％、EGCG 5-20％。
本发明提出的一种抗氧化辅助降血糖的中药组合物，将朱丹溪“消渴方”、“玉泉散”作为基本方，以养阴益气为主要治则发挥对机体的整体调节，结合天然的抗氧化活性成分EGCG与青钱柳、翻白草、荔枝核、龙眼核、木瓜核等现代降糖植物成分，实现显著降低血糖、增加糖耐量能力的同时通过抗氧化损伤和胰脏自噬功能以保护胰脏的功效，发挥出比基础方更强的降血糖和抗氧化药物效果。
可选地，所述提取物A，包括按重量份计的：生黄芪20份、生地15份、苍术7.5份、葛根15份、丹参15份、青钱柳7.5份、苦瓜15份、壳聚糖10份。
可选地，所述提取物B，包括按重量份计的：连钱草30份、杞子根30份、马齿苋15份、芥菜花15份、玉竹15份、麦冬15份、天花粉12份、丹参15份。
可选地，所述提取物C，包括按重量份计的：龙眼核35份、荔枝核35份、木瓜核35份。
可选地，所述提取物D，包括按重量份计的：翻白草140份。
本发明还提供一种抗氧化辅助降血糖的中药组合物的制备方法，包括以下步骤：
S1、称取生黄芪、生地、苍术、葛根、丹参、青钱柳和苦瓜加水进行浸泡，而后再加水提取，合并水提取液后过滤，滤液减压浓缩至稠膏，干燥，加入壳聚糖混合均匀，得到提取物A；
称取连钱草、杞子根、马齿苋、芥菜花、玉竹、麦冬、天花粉和丹参加水进行浸泡，而后再加水提取，合并水提取液后过滤，滤液减压浓缩至稠膏，干燥，得到提取物B；
称取龙眼核、荔枝核和木瓜核加水进行浸泡，而后再加水提取，合并水提取液后过滤，滤液减压浓缩至稠膏，干燥，得到提取物C；
称取翻白草加水进行浸泡，而后再加水提取，合并水提取液后过滤，滤液减压浓缩至稠膏，干燥，得到提取物D；
称取灵芝提取物和EGCG，混合，得到提取物E；
S2、将提取物A、提取物B、提取物C、提取物D和提取物E按比例混合，得到所述中药组合物。
可选地，步骤S1中，提取的条件包括：提取的次数为1-3次，每次提取时间为1-3h，每次提取的水用量为原料总重量的8-20倍。
可选地，步骤S1中，浸泡时间为1-4h；所述水提取液以200目过筛；所述稠膏的相对密度为1.05-1.2g/mL。
本发明还提供一种抗氧化辅助降血糖的中药组合物在制备治疗糖尿病的药物中的应用。
可选地，所述中药组合物的应用剂型包括片剂、颗粒剂、胶囊剂、丸剂或口服液体制剂。
附图说明
图1为本发明实验例中给药结束后各组对小鼠糖耐量影响图；
图2为本发明实验例中各组对小鼠糖耐量给药前后差值的影响图；
图3为本发明实验例中给药结束后各组对小鼠空腹血糖的影响图；
图4为本发明实验例中给药结束后各组对小鼠胰脏组织中谷胱甘肽过氧化物酶(GSH-PX)活力的影响图；
图5为本发明实验例中给药结束后各组对小鼠胰脏组织中丙二醛(MDA)含量的影响图。
具体实施方式
为了更好的理解上述技术方案，下面将参照附图更详细地描述本发明的示例性实施例。虽然附图中显示了本发明的示例性实施例，然而应当理解，可以以各种形式实现本发明而不应被这里阐述的实施例所限制。相反，提供这些实施例是为了能够更清楚、透彻地理解本发明，并且能够将本发明的范围完整的传达给本领域的技术人员。
实施例1
一种抗氧化辅助降血糖的中药组合物，包括按重量百分比计的：
提取物A 30％、提取物B 30％、提取物C15％、提取物D15％、提取物E10％；
所述提取物A，包括按重量份计的：生黄芪20g、生地15g、苍术7.5g、葛根15g、丹参15g、青钱柳7.5g、苦瓜15g、壳聚糖5g；
所述提取物B，包括按重量份计的：连钱草30g、杞子根30g、马齿苋15g、芥菜花15g、玉竹15g、麦冬15g、天花粉12g、丹参15g；
所述提取物C，包括按重量份计的：龙眼核40g、荔枝核40g、木瓜核34g；
所述提取物D，包括按重量份计的：翻白草100g；
所述提取物E，包括按重量百分比计的：灵芝提取物1％、EGCG 9％。
其通过下述方法制得：
S1、称取生黄芪、生地、苍术、葛根、丹参、青钱柳和苦瓜加水进行浸泡1h，而后再加水至原料总重量的8倍进行提取，共提取2次，每次提取1-3h，合并水提取液后以200目筛网过滤，滤液减压浓缩至相对密度为1.05-1.2g/mL的稠膏，干燥，加入壳聚糖混合均匀，得到提取物A；
称取连钱草、杞子根、马齿苋、芥菜花、玉竹、麦冬、天花粉和丹参加水进行浸泡1h，而后再加水至原料总重量的8倍进行提取，共提取2次，每次提取1-3h，合并水提取液后以200目筛网过滤，滤液减压浓缩至相对密度为1.05-1.2g/mL的稠膏，干燥，得到提取物B；
称取龙眼核、荔枝核和木瓜核加水进行浸泡1h，而后再加水至原料总重量的8倍进行提取，共提取2次，每次提取1-3h，合并水提取液后以200目筛网过滤，滤液减压浓缩至相对密度为1.05-1.2g/mL的稠膏，干燥，得到提取物C；
称取翻白草加水进行浸泡1h，而后再加水至原料总重量的8倍进行提取，共提取2次，每次提取1-3h，合并水提取液后以200目筛网过滤，滤液减压浓缩至相对密度为1.05-1.2g/mL的稠膏，干燥，得到提取物D；
称取灵芝提取物和EGCG，混合，得到提取物E。
S2、将提取物A、提取物B、提取物C、提取物D和提取物E按比例混合，得到所述中药组合物。
实施例2
一种抗氧化辅助降血糖的中药组合物颗粒剂的制备方法，包括如下步骤：
S1、称取生黄芪10g、生地10g、苍术5g、葛根10g、丹参15g、青钱柳7.5g和苦瓜15g加水进行浸泡1h，而后再加水至原料总重量的10倍进行提取，共提取3次，每次提取1-3h，合并水提取液后以200目筛网过滤，滤液减压浓缩至相对密度为1.05-1.2g/mL的稠膏，干燥，加入壳聚糖10g混合均匀，得到提取物A，其重量占比为27.5％；
称取连钱草20g、杞子根20g、马齿苋20g、芥菜花15g、玉竹15g、麦冬15g、天花粉12g和丹参15g加水进行浸泡1h，而后再加水至原料总重量的20倍进行提取，共提取2次，每次提取1-3h，合并水提取液后以200目筛网过滤，滤液减压浓缩至相对密度为1.05-1.2g/mL的稠膏，干燥，得到提取物B，其重量占比为27.5％；
称取龙眼核34g、荔枝核34g和木瓜核34g加水进行浸泡1h，而后再加水至原料总重量的15倍进行提取，共提取2次，每次提取1-3h，合并水提取液后以200目筛网过滤，滤液减压浓缩至相对密度为1.05-1.2g/mL的稠膏，干燥，得到提取物C，其重量占比为15％；
称取翻白草150g加水进行浸泡1h，而后再加水至原料总重量的10倍进行提取，共提取2次，每次提取1-3h，合并水提取液后以200目筛网过滤，滤液减压浓缩至相对密度为1.05-1.2g/mL的稠膏，干燥，得到提取物D，其重量占比为15％；
称取灵芝提取物5％和EGCG 10％，混合，得到提取物E。
S2、将提取物A、提取物B、提取物C、提取物D和提取物E按比例混合，得到所述中药组合物。
S3、将预胶化淀粉200g与中药组合物100g混合，用10％淀粉浆，湿法造粒，再用14目的筛网湿法制粒，湿颗粒经干燥即得。
实施例3
一种抗氧化辅助降血糖的中药组合物片剂的制备方法，包括如下步骤：
S1、称取生黄芪30g、生地15g、苍术5g、葛根10g、丹参15g、青钱柳7.5g和苦瓜15g加水进行浸泡2h，而后再加水至原料总重量的10倍进行提取，共提取3次，每次提取1-3h，合并水提取液后以200目筛网过滤，滤液减压浓缩至相对密度为1.05-1.2g/mL的稠膏，干燥，加入壳聚糖15g混合均匀，得到提取物A，其重量占比为30％；
称取连钱草30g、杞子根20g、马齿苋20g、芥菜花15g、玉竹15g、麦冬15g、天花粉12g和丹参15g加水进行浸泡2h，而后再加水至原料总重量的20倍进行提取，共提取2次，每次提取1-3h，合并水提取液后以200目筛网过滤，滤液减压浓缩至相对密度为1.05-1.2g/mL的稠膏，干燥，得到提取物B，其重量占比为30％；
称取龙眼核25g、荔枝核25g和木瓜核25g加水进行浸泡2h，而后再加水至原料总重量的15倍进行提取，共提取2次，每次提取1-3h，合并水提取液后以200目筛网过滤，滤液减压浓缩至相对密度为1.05-1.2g/mL的稠膏，干燥，得到提取物C，其重量占比为15％；
称取翻白草300g加水进行浸泡2h，而后再加水至原料总重量的10倍进行提取，共提取2次，每次提取1-3h，合并水提取液后以200目筛网过滤，滤液减压浓缩至相对密度为1.05-1.2g/mL的稠膏，干燥，得到提取物D，其重量占比为15％；
称取灵芝提取物4％和EGCG 6％，混合，得到提取物E。
S2、将提取物A、提取物B、提取物C、提取物D和提取物E按比例混合，得到所述中药组合物。
S3、将预胶化淀粉100g与中药组合物100g混合，用10％淀粉浆，湿法造粒，再用14目的筛网湿法制粒，湿颗粒经干燥，整理，再加入1％的硬脂酸镁，混匀，经压片，即得。
实施例4
一种抗氧化辅助降血糖的中药组合物胶囊剂的制备方法，包括如下步骤：
S1、称取生黄芪30g、生地15g、苍术5g、葛根10g、丹参15g、青钱柳7.5g和苦瓜15g加水进行浸泡1.5h，而后再加水至原料总重量的10倍进行提取，共提取3次，每次提取1-3h，合并水提取液后以200目筛网过滤，滤液减压浓缩至相对密度为1.05-1.2g/mL的稠膏，干燥，加入壳聚糖5g混合均匀，得到提取物A，其重量占比为25％；
称取连钱草25g、杞子根20g、马齿苋20g、芥菜花15g、玉竹15g、麦冬15g、天花粉12g和丹参15g加水进行浸泡1.5h，而后再加水至原料总重量的15倍进行提取，共提取2次，每次提取1-3h，合并水提取液后以200目筛网过滤，滤液减压浓缩至相对密度为1.05-1.2g/mL的稠膏，干燥，得到提取物B，其重量占比为25％；
称取龙眼核30g、荔枝核30g和木瓜核30g加水进行浸泡2h，而后再加水至原料总重量的10倍进行提取，共提取2次，每次提取1-3h，合并水提取液后以200目筛网过滤，滤液减压浓缩至相对密度为1.05-1.2g/mL的稠膏，干燥，得到提取物C，其重量占比为15％；
称取翻白草300g加水进行浸泡1.5h，而后再加水至原料总重量的10倍进行提取，共提取2次，每次提取1-3h，合并水提取液后以200目筛网过滤，滤液减压浓缩至相对密度为1.05-1.2g/mL的稠膏，干燥，得到提取物D，其重量占比为15％；
称取灵芝提取物5％和EGCG 15％，混合，得到提取物E。
S2、将提取物A、提取物B、提取物C、提取物D和提取物E按比例混合，得到所述中药组合物。
S3、将预胶化淀粉100g与中药组合物100g混合，用10％淀粉浆，湿法造粒，再用14目的筛网湿法制粒，湿颗粒经干燥，整理，再加入1％的硬脂酸镁，混匀，经胶囊填充，即得。
实验例
1.实验动物
70只8周龄的ICR小鼠，适应性饲养1周后开始实验。
2.实验药物
受试药物为本发明中药组合物：由本实施例1按照人每日服用4.8g干固物的量进行供试样品制备；阳性对照药为玉泉丸和EGCG。
给药量：人用剂量为95g生药/60kg人，即1.58g/kg；小鼠剂量为1.58*20＝31.6g生药/kg体重，按照每10g体重给药体积为0.1mL，则：配制浓度为＝31.6/(100*0.1)＝3.16生药/mL。
3.实验方法
3.1实验建模、分组及给药
将适应性饲养1周后的小鼠随机分为两组：取10只小鼠作为空白对照组，给予普通饲料喂养；其余60只小鼠为造模组，给予高脂饲料(基础饲料+20％炼猪油+10％蔗糖)喂养，两组小鼠均自由饮水、摄食。4周后造模组小鼠单次腹腔注射STZ 70mg/kg(称取STZ配成1％的枸橼酸盐溶液)，1周后再次腹腔注射STZ 60mg/kg；空白组小鼠腹腔注射等体积的STZ。禁食12小时以上(一般过夜禁食，不禁水)，禁食的时间越长，STZ对胰岛β细胞的破坏力越明显，即药效越高。所以相对禁食时间延长，可以降低STZ的用量。分别于注射7d时，将小鼠禁食12h于次日清晨尾尖采血，测小鼠空腹血糖(Fasting blood-glucose,FBG)值，造模组小鼠空腹血糖值均>11mmol/L，则2型糖尿病小鼠模型建立成功。
将60只造模成功的2型糖尿病小鼠再随机分为6组：模型组、玉泉丸组、中药复方组、EGCG组，每组各10只。空白组和模型组给予等容量生理盐水灌胃(1mL/100g)，玉泉丸组、EGCG组和中药复方组给予等效剂量的2.5倍及临床剂量的25倍中药药液灌胃。各组小鼠饮食不变，一日1次，连续给药8周。
3.2检测指标及方法
3.2.1口服葡萄糖耐量实验
实验时小鼠过夜禁食12h，空腹采血后灌胃给予50％葡萄糖液(2g/kg)，眼眶采血，测定第30、60、120min血糖，分别于给药前和给药后测定糖耐量。
3.2.2空腹血糖检测
灌胃给药结束后，小鼠禁食12h，尾尖采血，使用血糖仪测定空腹血糖。
3.2.3抗氧化性能测试
胰腺组织加入适量冷裂解液研磨匀浆，制备成10％的组织匀浆，3000r/min低温离心10min后取上清液，按照试剂盒要求，分别测定糖尿病模型小鼠胰脏组织中谷胱甘肽过氧化物酶(GSH-PX)活力和丙二醛(MDA)含量。
4.实验结果
4.1糖耐量对比
从表1-2和图1-2可以看出，本发明的中药组合物对STZ与高脂饲料所致2型糖尿病小鼠的糖耐量有一定的降低作用，且治疗前后比较有显著性差异(P<0.05)。
表1
表2
4.2空腹血糖对比
由表3和图3可知，与空白组比较，模型组血糖值显著升高(P<0.0001)，说明造模成功；与模型组相比，本发明的中药组合物能显著降低以高脂饲料联合STZ诱导糖尿病模型小鼠的血糖值(P<0.05)，且作用效果优于其他实验对照组。
表3
4.3抗氧化性能对比
结合表4和图4-5可知，本发明的中药组合物对GSH-PX的活力水平有明显的提高作用(P<0.05)，且对MDA水平有一定的降低作用(P<0.01)，表明本发明的中药组合物能提高糖尿病小鼠胰脏组织的抗氧化能力，减轻胰腺组织的损伤，且效果优于基础药物玉泉丸组和EGCG组。
表4
现代医学表明中药的抗氧化作用对降低血糖具有较好的效果，中药降血糖的主要成分按化学结构可分为多糖、生物碱、皂苷、黄酮等四大类。本发明方中的多数原料都含有上述活性成分的至少一种，如黄芪、葛根含黄酮、多糖等成分；生地、苍术、丹参、壳聚糖、马齿苋、灵芝含有多糖等成分；苦瓜、玉竹、麦冬含有多糖、皂苷等成分；翻白草含有黄酮等成分；杞子根、EGCG、龙眼核含有多酚等成分；荔枝核含有皂苷、黄酮等成分；木瓜核含有多酚、黄酮等成分。纵观本发明诸药配伍，将抗氧化这一现代医学理念对血糖的影响与传统中医的益气养阴、清热生津、理气化瘀的功能进行嫁接，共奏降血糖之功效。
最后应说明的是：以上各实施例仅用以说明本发明的技术方案，而非对其限制；尽管参照前述各实施例对本发明进行了详细的说明，本领域的普通技术人员应当理解：其依然可以对前述各实施例所记载的技术方案进行修改，或者对其中部分或者全部技术特征进行等同替换；而这些修改或者替换，并不使相应技术方案的本质脱离本发明各实施例技术方案的范围。
Claims (10)
1.一种抗氧化辅助降血糖的中药组合物，包括按重量百分比计的：
提取物A 20-30％、提取物B 20-30％、提取物C15％、提取物D15％、提取物E10-20％；
所述提取物A，包括按重量份计的：生黄芪10-30份、生地10-20份、苍术5-10份、葛根10-20份、丹参10-20份、青钱柳5-10份、苦瓜10-30份、壳聚糖5-15份；
所述提取物B，包括按重量份计的：连钱草20-40份、杞子根20-40份、马齿苋10-30份、芥菜花10-30份、玉竹10-30份、麦冬10-30份、天花粉10-30份、丹参10-30份；
所述提取物C，包括按重量份计的：龙眼核20-40份、荔枝核20-40份、木瓜核20-40份；
所述提取物D，包括按重量份计的：翻白草100-300份；
所述提取物E，包括按重量百分比计的：灵芝提取物1-10％、EGCG 5-20％。
2.如权利要求1所述的抗氧化辅助降血糖的中药组合物，其特征在于，所述提取物A，包括按重量份计的：生黄芪20份、生地15份、苍术7.5份、葛根15份、丹参15份、青钱柳7.5份、苦瓜15份、壳聚糖10份。
3.如权利要求1所述的抗氧化辅助降血糖的中药组合物，其特征在于，所述提取物B，包括按重量份计的：连钱草30份、杞子根30份、马齿苋15份、芥菜花15份、玉竹15份、麦冬15份、天花粉12份、丹参15份。
4.如权利要求1所述的抗氧化辅助降血糖的中药组合物，其特征在于，所述提取物C，包括按重量份计的：龙眼核35份、荔枝核35份、木瓜核35份。
5.如权利要求1所述的抗氧化辅助降血糖的中药组合物，其特征在于，所述提取物D，包括按重量份计的：翻白草140份。
6.一种如权利要求1-5中任一项所述的抗氧化辅助降血糖的中药组合物的制备方法，包括以下步骤：
S1、称取生黄芪、生地、苍术、葛根、丹参、青钱柳和苦瓜加水进行浸泡，而后再加水提取，合并水提取液后过滤，滤液减压浓缩至稠膏，干燥，加入壳聚糖混合均匀，得到提取物A；
称取连钱草、杞子根、马齿苋、芥菜花、玉竹、麦冬、天花粉和丹参加水进行浸泡，而后再加水提取，合并水提取液后过滤，滤液减压浓缩至稠膏，干燥，得到提取物B；
称取龙眼核、荔枝核和木瓜核加水进行浸泡，而后再加水提取，合并水提取液后过滤，滤液减压浓缩至稠膏，干燥，得到提取物C；
称取翻白草加水进行浸泡，而后再加水提取，合并水提取液后过滤，滤液减压浓缩至稠膏，干燥，得到提取物D；
称取灵芝提取物和EGCG，混合，得到提取物E；
S2、将提取物A、提取物B、提取物C、提取物D和提取物E按比例混合，得到所述中药组合物。
7.如权利要求6所述的制备方法，其特征在于，步骤S1中，提取的条件包括：提取的次数为1-3次，每次提取时间为1-3h，每次提取的水用量为原料总重量的8-20倍。
8.如权利要求6所述的制备方法，其特征在于，步骤S1中，浸泡时间为1-4h；所述水提取液以200目过筛；所述稠膏的相对密度为1.05-1.2g/mL。
9.一种如权利要求1-5中任一项所述的抗氧化辅助降血糖的中药组合物在制备治疗糖尿病的药物中的应用。
10.如权利要求9所述的应用，其特征在于，所述中药组合物的应用剂型包括片剂、颗粒剂、胶囊剂、丸剂或口服液体制剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311498090.7A CN117599134A (zh) | 2023-11-10 | 2023-11-10 | 一种抗氧化辅助降血糖的中药组合物及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311498090.7A CN117599134A (zh) | 2023-11-10 | 2023-11-10 | 一种抗氧化辅助降血糖的中药组合物及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117599134A true CN117599134A (zh) | 2024-02-27 |
Family
ID=89955384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311498090.7A Pending CN117599134A (zh) | 2023-11-10 | 2023-11-10 | 一种抗氧化辅助降血糖的中药组合物及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117599134A (zh) |
-
2023
- 2023-11-10 CN CN202311498090.7A patent/CN117599134A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101411760B (zh) | 苹果属花楸苹果组植物的新用途 | |
| CN106606529A (zh) | 一种具有辅助降血糖功效的组合物及其制备方法和应用 | |
| CN102100874A (zh) | 一种治疗糖尿病的中成药及其制备方法 | |
| CN108524814A (zh) | 一种用于降低血糖的中药组合物及其制备方法 | |
| CN103300188A (zh) | 一种苦荞降糖颗粒茶及其制作方法 | |
| CN106421359A (zh) | 一种全面治疗糖尿病及其并发症的药物组合物 | |
| CN102579836A (zh) | 一种霍山石斛中药组合物及其制备方法 | |
| CN106924374A (zh) | 一种组合物及其制备方法与在制备降血糖和/或降血脂的产品中的应用 | |
| CN107006856A (zh) | 一种增强耐力、提高抗缺氧耐受力营养剂及其制备方法 | |
| CN101856405A (zh) | 一种治疗2型糖尿病的药物组合物及其制备方法 | |
| CN102727753B (zh) | 一种用于治疗痛风的中药组合物及其制备方法和应用 | |
| CN103520376A (zh) | 一种具有辅助降血糖作用的中药养生制剂 | |
| CN103705578B (zh) | 具有降血脂与抑制血糖升高作用的中药制剂及其制备方法 | |
| CN1329067C (zh) | 治疗糖尿病的中药制剂 | |
| CN102579587B (zh) | 一种防治糖尿病及其并发症的中药组合物 | |
| CN102631415B (zh) | 中药组合物及其制成品和用途 | |
| CN105327115B (zh) | 一种防治ⅱ型糖尿病桑黄通泻配方及制备工艺 | |
| CN117599134A (zh) | 一种抗氧化辅助降血糖的中药组合物及其制备方法和应用 | |
| KR100376030B1 (ko) | 2형 당뇨에 효능이 있는 생약제제 | |
| CN114209758A (zh) | 一种具有维持血糖健康水平的中药复方组合物及其制备方法与应用 | |
| CN103933282B (zh) | 一种治疗糖尿病的中药胶囊 | |
| CN104474103A (zh) | 一种天然植物降糖剂及其制备方法 | |
| CN103961551A (zh) | 一种治疗糖尿病的藏药 | |
| CN108743885A (zh) | 一种治疗糖尿病大血管病变的中药及其制备方法 | |
| CN103989940A (zh) | 一种治疗糖尿病的中药组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |